FDA De Novo Classification Strategy

The Initial Challenge

At the outset of the engagement, the client faced a familiar dilemma encountered by many innovators introducing first-of-their-kind medical technologies.

The engineering team successfully demonstrated algorithm performance through internal testing and retrospective analyses. User interface development had progressed rapidly, cybersecurity architecture had been designed using recognized industry frameworks, and software verification activities were well underway. However, regulatory planning had not advanced at the same pace.

Management conducted preliminary searches of FDA’s public databases and identified several AI-related medical devices with seemingly comparable capabilities. A deeper analysis performed by E&E Medicals revealed important distinctions. Although some products used artificial intelligence or software analytics, their intended uses, clinical indications, target populations, and technological characteristics differed substantially from the client’s product.

Without an appropriate predicate device, a Traditional 510(k) would likely fail because the FDA could conclude that the product raised different questions of safety and effectiveness.

The company needed clarity before committing millions of dollars to additional verification testing and clinical studies.

Regulatory Assessment

Press enter or click to view image in full size

E&E Medicals and Consulting initiated the project with a comprehensive regulatory assessment designed to answer one fundamental question: Which FDA pathway offered the greatest likelihood of successful commercialization?

The assessment examined the product from multiple perspectives, including:

· Intended use and indications for use